SCHEMBL2901676

SCHEMBL2901676

COc1cc2c(=O)n(-c3ncc(OC)c(OC)n3)c(=S)[nH]c2cc1C(=O)NCc1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.48
▸ EGLN3 Q9H6Z9 3/20 0.47
▸ RXFP1 Q9HBX9 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ POLB P06746 1/20 0.42
▸ APEX1 P27695 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ PDE5A O76074 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ DYRK1B Q9Y463 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897657 0.95 EGLN3 (0.46) PDE10AEGLN3RXFP1MEN1KMT2A
SCHEMBL2895002 0.94 PDE10A (0.46) PDE10AEGLN3RXFP1MEN1KMT2A
SCHEMBL3587221 0.92 EGLN3 (0.56) EGLN3MEN1KMT2AMAPTPDE5A
SCHEMBL2901148 0.90 KMT2A (0.55) EGLN3MEN1KMT2APOLBMAPT
SCHEMBL2894984 0.89 EGLN3 (0.59) PDE10AEGLN3RXFP1MEN1KMT2A
SCHEMBL2901724 0.88 EGLN3 (0.45) PDE10AEGLN3MEN1KMT2APOLB
SCHEMBL2899480 0.87 MAPT (0.46) EGLN3RXFP1MEN1KMT2AMAPT
SCHEMBL2900574 0.86 EGLN3 (0.55) EGLN3MEN1KMT2AMAPTPDE5A
SCHEMBL2903273 0.85 EGLN3 (0.48) PDE10AEGLN3MEN1KMT2APOLB
SCHEMBL2900770 0.85 EGLN3 (0.54) PDE10AEGLN3MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US claimed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP claimed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO claimed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 PDE10A 2458/4885EGLN3 2/4885RXFP1 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback